Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Verlagsversion
DOI
PMC
 |
Open Access Gold (Paid Option) |
|
möglich sobald bei der ZB eingereicht worden ist.
Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction.
Eur. J. Heart Fail. 23, 1633-1644 (2021)
Verlagsversion
DOI
PMC
AIMS: Recent evidence points towards a distinct obese phenotype among patients with heart failure with preserved ejection fraction (HFpEF). We aimed to identify differentially expressed circulating biomarkers in obese HFpEF patients and link them to disease severity and outcomes. METHODS AND RESULTS: From the LIFE-Heart study, 999 patients with HFpEF and 999 patients without heart failure (no-HF) were selected and 92 circulating serum biomarkers were measured using a proximity extension assay. Elevation of identified biomarkers was validated in 220 patients from the Aldo-DHF trial with diagnosed HFpEF. HFpEF patients were older and had more comorbidities including coronary artery disease and type 2 diabetes as compared to no-HF patients (p<0.05 for all). After adjusting for covariates, Adrenomedullin (ADM), Galectin-9 (Gal-9), Thrombospondin-2 (THBS-2), CD4, and TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) were significantly higher in obese HFpEF (BMI≥30 kg/m2 , n=464) patients as compared to lean HFpEF (BMI<30 kg/m2 , n=535) and obese no-HF patients (BMI≥30 kg/m2 , n=387) (p<0.001 for both), those findings were verified in the Aldo-DHF validation cohort (p<0.001). Except for CD4 these proteins were associated with increased estimates of left atrial pressure in a linear fashion. Importantly, ADM, TRAIL-R2 and CD4 were associated with increased mortality in obese HFpEF patients after adjusting for covariates. CONCLUSION: Obese HFpEF patients exhibit higher circulating biomarkers of volume expansion (ADM), myocardial fibrosis (THBS-2) and systemic inflammation (Gal-9, CD4) compared to obese non-HFpEF or lean HFpEF. These findings support the clinical definition of a distinct obese HFpEF phenotype and might merit further investigation. This article is protected by copyright. All rights reserved.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Hfpef ; Heart Failure With Preserved Ejection Fraction ; Biomarker ; Fibrosis ; Inflammation ; Obesity ; Proteomics; Epicardial Adipose-tissue; Inflammation; Thrombospondin-2; Adrenomedullin; Expression; Galectin-9; Dhf
ISSN (print) / ISBN
1388-9842
e-ISSN
1879-0844
Zeitschrift
European Journal of Heart Failure
Quellenangaben
Band: 23,
Heft: 10,
Seiten: 1633-1644
Verlag
Wiley
Verlagsort
111 River St, Hoboken 07030-5774, Nj Usa
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Förderungen
University of Gottingen
Federal Ministry of Education and Research
German Competence Network of Heart Failure
Free State of Saxony
European Regional Development Fund (ERDF)
European Union
University of Leipzig
HELIOS
Federal Ministry of Education and Research
German Competence Network of Heart Failure
Free State of Saxony
European Regional Development Fund (ERDF)
European Union
University of Leipzig
HELIOS